Biodistribution and Dosimetry of the Investigational PET Agent Ga-68 P16-093 in Prostate Cancer Patients With Biochemical Recurrence Undergoing Clinical Ga-68 PSMA-11 PET/CT

Trial Profile

Biodistribution and Dosimetry of the Investigational PET Agent Ga-68 P16-093 in Prostate Cancer Patients With Biochemical Recurrence Undergoing Clinical Ga-68 PSMA-11 PET/CT

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Gallium-68-P16-093 (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Sponsors Five Eleven Pharma
  • Most Recent Events

    • 27 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top